Melanoma and Immune Checkpoint Inhibitors

Masutaka Furue, Takamichi Ito, Naoko Wada, Maiko Wada, Takafumi Kadono, Uchi Hiroshi

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Purpose of Review: Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients. Here we will review the recent clinical efficacy and adverse events of immune checkpoint inhibitors for melanoma patients. Recent Findings: The immune checkpoint inhibitors increase confirmed objective response and prolong progression-free and overall survival of the afflicted patients in association with maintaining their quality of life. Although diverse immune-related adverse events occur, most of them are manageable by appropriate immunomodulating agents. Clinical efficacy of immune checkpoint inhibitors continues even after discontinuation of drugs. Summary: Compared with conventional therapeutic options, the immune checkpoint inhibitors appear to prolong the survival of patients with advanced melanoma. Further clinical trials are warranted to determine whether their combinatory use with other treatment options may augment benefits or not.

Original languageEnglish
Article number29
JournalCurrent Oncology Reports
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Melanoma
Survival
Disease-Free Survival
Quality of Life
Clinical Trials
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Melanoma and Immune Checkpoint Inhibitors. / Furue, Masutaka; Ito, Takamichi; Wada, Naoko; Wada, Maiko; Kadono, Takafumi; Hiroshi, Uchi.

In: Current Oncology Reports, Vol. 20, No. 3, 29, 01.03.2018.

Research output: Contribution to journalReview article

Furue, Masutaka ; Ito, Takamichi ; Wada, Naoko ; Wada, Maiko ; Kadono, Takafumi ; Hiroshi, Uchi. / Melanoma and Immune Checkpoint Inhibitors. In: Current Oncology Reports. 2018 ; Vol. 20, No. 3.
@article{ce4729edb6df43b99a871b9aaab87f3a,
title = "Melanoma and Immune Checkpoint Inhibitors",
abstract = "Purpose of Review: Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10{\%}. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients. Here we will review the recent clinical efficacy and adverse events of immune checkpoint inhibitors for melanoma patients. Recent Findings: The immune checkpoint inhibitors increase confirmed objective response and prolong progression-free and overall survival of the afflicted patients in association with maintaining their quality of life. Although diverse immune-related adverse events occur, most of them are manageable by appropriate immunomodulating agents. Clinical efficacy of immune checkpoint inhibitors continues even after discontinuation of drugs. Summary: Compared with conventional therapeutic options, the immune checkpoint inhibitors appear to prolong the survival of patients with advanced melanoma. Further clinical trials are warranted to determine whether their combinatory use with other treatment options may augment benefits or not.",
author = "Masutaka Furue and Takamichi Ito and Naoko Wada and Maiko Wada and Takafumi Kadono and Uchi Hiroshi",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s11912-018-0676-z",
language = "English",
volume = "20",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Melanoma and Immune Checkpoint Inhibitors

AU - Furue, Masutaka

AU - Ito, Takamichi

AU - Wada, Naoko

AU - Wada, Maiko

AU - Kadono, Takafumi

AU - Hiroshi, Uchi

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose of Review: Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients. Here we will review the recent clinical efficacy and adverse events of immune checkpoint inhibitors for melanoma patients. Recent Findings: The immune checkpoint inhibitors increase confirmed objective response and prolong progression-free and overall survival of the afflicted patients in association with maintaining their quality of life. Although diverse immune-related adverse events occur, most of them are manageable by appropriate immunomodulating agents. Clinical efficacy of immune checkpoint inhibitors continues even after discontinuation of drugs. Summary: Compared with conventional therapeutic options, the immune checkpoint inhibitors appear to prolong the survival of patients with advanced melanoma. Further clinical trials are warranted to determine whether their combinatory use with other treatment options may augment benefits or not.

AB - Purpose of Review: Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients. Here we will review the recent clinical efficacy and adverse events of immune checkpoint inhibitors for melanoma patients. Recent Findings: The immune checkpoint inhibitors increase confirmed objective response and prolong progression-free and overall survival of the afflicted patients in association with maintaining their quality of life. Although diverse immune-related adverse events occur, most of them are manageable by appropriate immunomodulating agents. Clinical efficacy of immune checkpoint inhibitors continues even after discontinuation of drugs. Summary: Compared with conventional therapeutic options, the immune checkpoint inhibitors appear to prolong the survival of patients with advanced melanoma. Further clinical trials are warranted to determine whether their combinatory use with other treatment options may augment benefits or not.

UR - http://www.scopus.com/inward/record.url?scp=85044267770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044267770&partnerID=8YFLogxK

U2 - 10.1007/s11912-018-0676-z

DO - 10.1007/s11912-018-0676-z

M3 - Review article

C2 - 29569208

AN - SCOPUS:85044267770

VL - 20

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 3

M1 - 29

ER -